Our website would like to use cookies to store information on your computer. You may delete and block all cookies from this site, but parts of the site will not work as a result. Find out more about how we use cookies.
 IAPO - International Alliance of Patients' Organizations IAPO - International Alliance of Patients' Organizations  
  Feedback   Search   Contact Us   Languages   Sitemap
 
 IAPO - International Alliance of Patients' Organizations   IAPO - A Global Voice for Patients IAPO - A Global Voice for Patients IAPO - A Global Voice for Patients IAPO - A Global Voice for Patients
 IAPO - International Alliance of Patients' Organizations  IAPO Home Page IAPO Alliance IAPO News IAPO Patient Centred Healthcare IAPO Membership IAPO Patients' Exchange IAPO Community
  IAPO - International Alliance of Patients' Organizations
 

 
     
  Login>
Fogotten Password>

 
 
All Content © 2009
Legal Disclaimer


 
 
PROTECT
by IAPO at 5:34PM Wednesday 08 May 2013 (News)

Update: IAPO and the benefit-risk of medicines in Europe
Since 2009, IAPO has been a partner in a European project, the Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT). PROTECT aims to strengthen the monitoring of the benefit-risk of medicines. IAPO is currently supporting two of the Work Packages within this project.

WP4: New methods for data collection from consumers
The overall objective of WP4 is to explore the feasibility and added value of modern methods for collecting data directly from consumers.

WP5: Benefit-risk integration and representation
The overall objective of WP5 is to develop methods for use in benefit-risk assessment, including both the underpinning modelling and the presentation of the results, with a particular emphasis on graphical methods. The various options will be compared and tested out on a range of case-studies with patients, healthcare providers, pharma industry and regulators.

About PROTECT
PROTECT is a collaborative European project that comprises a programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The goal of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. This will be achieved by developing a set of innovative tools and methods that will enhance the early detection and assessment of adverse drug reactions from different data sources, and enable the integration and presentation of data on benefits and risks. These methods will be tested in real-life situations in order to provide all stakeholders (patients, prescribers, public health authorities, regulators and pharmaceutical companies) with accurate and useful information supporting risk management and continuous benefit-risk assessment.

For more information see: www.imi-protect.eu.

Attachments...
JPG image
PrintPrint


Powered by
Powered by Novacaster